Adalimumab-induced sarcoid-like reaction during treatment for Crohn’s disease：a case report
Yoko Kida(Kobe City Nishi-Kobe Medical Center), Kimihide Tada, Naoko Hamazaki(Kobe City Nishi-Kobe Medical Center), Rikiya Koketsu(Kobe City Nishi-Kobe Medical Center), Toshiyasu Sakurai(Kobe City Nishi-Kobe Medical Center), Takahiro Masuda(Jichi Medical University), Sayaka Fujimoto(Kobe City Nishi-Kobe Medical Center), Masatsugu Yamamoto(Kobe Medical Center), Fumiko Yshiyama, Akihiro Oshima, Maki Kanazawa(Kobe City Nishi-Kobe Medical Center), Soichiro Yoshimura, Takuya Inoue, Hiroki Sato, Nanako Miwa(Kobe University), Kosuke Tokushige(Kobe Medical Center)
The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders
October 1, 2025
Cited by 0
Related Papers
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
|American Journal of Physiology-Renal Physiology|2013|481
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia
|American Journal of Physiology-Renal Physiology|2013|308
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
|American Journal of Physiology-Renal Physiology|2012|158
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin‐induced water reabsorption to maintain body fluid volume
|Physiological Reports|2020|135